Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and β-cell function in patients with type 2 diabetes

被引:114
作者
Brazg, R.
Xu, L.
Dalla Man, C.
Cobelli, C.
Thomas, K.
Stein, P. P.
机构
[1] Merck Res Labs, Rahway, NJ 07065 USA
[2] Rainier Clin Res Ctr, Renton, WA USA
[3] Univ Padua, Dept Informat Engn, Padua, Italy
关键词
beta cell function; DPP-IV inhibitor; incretin; glycaemic control; MK-0431;
D O I
10.1111/j.1463-1326.2006.00691.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: The aim of this study was to assess the effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on 24-h glucose control when added to the regimen of patients with type 2 diabetes who had inadequate glycaemic control on metformin therapy. Methods: In a double-blind, randomized, placebo-controlled, two-period crossover study, patients with type 2 diabetes with inadequate glycaemic control on metformin monotherapy (i.e. on a stable dose of >= 1500 mg/day for >= 6 weeks prior to the screening visit and an haemoglobin A(1c) (HbA(1c)) >= 6.5% and < 10% and fasting plasma glucose (FPG) <= 240 mg/dl) were recruited for participation. A total of 28 patients (baseline HbA(1c) range = 6.5-9.6%) receiving metformin were randomized into one of two treatment sequences: the addition of placebo for 4 weeks followed by the addition of sitagliptin 50 mg twice daily (b.i.d.) for 4 weeks, or vice versa. At the end of each treatment period, patients were domiciled for frequent blood sampling over 24 h. The primary endpoint was 24-h weighted mean glucose (WMG) and secondary endpoints included change in FPG, mean of 7 daily self-blood glucose measurements (MDG) and fructosamine. beta-cell function was assessed from glucose and C-peptide concentrations were measured during the 5-h period after a standard breakfast meal by using the C-peptide minimal model. Results: Despite a carryover effect from period 1 to period 2, the combined period 1 and period 2 results for glycaemic endpoints were statistically significant for sitagliptin relative to placebo when added to ongoing metformin therapy. To account for the carryover effect, the period 1 results were also compared between the groups. Following period 1, there were significant least-squares (LS) mean reductions in 24-h WMG of 32.8 mg/dl, significant LS mean reduction from baseline in MDG of 28 mg/dl, FPG of 20.3 mg/dl and fructosamine of 33.7 mmol/l in patients treated with sitagliptin relative to placebo (p < 0.05). When added to ongoing metformin therapy, parameters of beta-cell function were significantly improved with sitagliptin compared with placebo. No weight gain or increases in gastrointestinal adverse events or hypoglycaemia events were observed with sitagliptin relative to placebo during this study. Conclusions: In this study, the addition of sitagliptin 50 mg b.i.d. to ongoing metformin therapy improved 24-h glycaemic control and beta-cell function, and was generally well tolerated in patients with type 2 diabetes.
引用
收藏
页码:186 / 193
页数:8
相关论文
共 13 条
  • [1] Insulin secretion rate during glucose stimuli: Alternative analyses of C-peptide data
    Breda, E
    Cobelli, C
    [J]. ANNALS OF BIOMEDICAL ENGINEERING, 2001, 29 (08) : 692 - 700
  • [2] Inhibitors of dipeptidyl peptidase IV:: a novel approach for the prevention and treatment of Type 2 diabetes?
    Deacon, CF
    Ahrén, B
    Holst, JJ
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (09) : 1091 - 1102
  • [3] Enhancing incretin action for the treatment of type 2 diabetes
    Drucker, DJ
    [J]. DIABETES CARE, 2003, 26 (10) : 2929 - 2940
  • [4] Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses
    Herman, GA
    Stevens, C
    Van Dyck, K
    Bergman, A
    Yi, BM
    De Smet, M
    Snyder, E
    Hilliard, D
    Tanen, M
    Tanaka, W
    Wang, AQ
    Zeng, W
    Musson, D
    Winchell, G
    Davies, MJ
    Ramael, S
    Gottesdiener, KM
    Wagner, JA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (06) : 675 - 688
  • [5] Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes
    Herman, Gary A.
    Bergman, Arthur
    Yi, Bingming
    Kipnes, Mark
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (10) : 1939 - 1947
  • [6] Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
    Herman, Gary A.
    Bergman, Arthur
    Stevens, Catherine
    Kotey, Paul
    Yi, Bingming
    Zhao, Peng
    Dietrich, Bruno
    Golor, George
    Schrodter, Andreas
    Keymeulen, Bart
    Lasseter, Kenneth C.
    Kipnes, Mark S.
    Snyder, Karen
    Hilliard, Deborah
    Tanen, Michael
    Cilissen, Caroline
    De Smet, Marina
    de Lepeleire, Inge
    Van Dyck, Kristien
    Wang, Amy Q.
    Zeng, Wei
    Davies, Michael J.
    Tanaka, Wesley
    Holst, Jens J.
    Deacon, Carolyn F.
    Gottesdiener, Keith M.
    Wagner, John A.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (11) : 4612 - 4619
  • [7] Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus
    Holst, JJ
    Deacon, CF
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2004, 4 (06) : 589 - 596
  • [8] Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
    Holst, JJ
    Gromada, J
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2004, 287 (02): : E199 - E206
  • [9] Inhibition of the activity of dipeptidyl peptidase IV as a treatment for type 2 diabetes
    Holst, JJ
    Deacon, CF
    [J]. DIABETES, 1998, 47 (11) : 1663 - 1670
  • [10] Oral antihyperglycemic therapy for type 2 diabetes - Scientific review
    Inzucchi, SE
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (03): : 360 - 372